Genmab — December 2012
-
very encouring data in the 1000 mg
-
the talk around the poster
-
flippy score betød ikke noget
-
som er udtryk for hvor slemt det er med FL´en
-
det skal bare på markedet Nicolai
-
ny poster
-
Ofa + ESHAP - en anden klassiker
-
Relapsed CHL
-
Overall response
-
god meget flot i relapsed
-
god sikkerhed
-
Så kører der OFA med Lenalidomide
-
orr i FL var 83%
-
og 1 års PFS 67%
-
Man skal huske på at dette er ikke Genmabs posters
-
men de sponsorerede forsøg
-
og kommer direkte fra deres posters
-
in vitro og in vivo er ofa bedre end rituxian i MCL
-
der er lavet noget sekventiel dosering mellem ofa og lenalidomide
-
i cll refrac
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind